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Introduction
Historically wrought in controversy, numerous studies in
experimental model systems have in the past decade provided
strong evidence for a role of the immune system in controlling
spontaneously occurring cancers.1 In this regard, perforin-defi-
cient mice have been reported to spontaneously develop B-cell
lymphomas, implicating lymphocyte cytotoxicity in immuno-
surveillance of hematologic malignancies.2 In humans, per-
forin-deficiency caused by hypomorphic mutations in PRF1
have been associated with hematologic malignancies, ranging
from lymphoma to leukemia, in children and adults.3,4
Autosomal recessive, nonsense mutations in PRF1 typically
present with hemophagocytic lymphohistiocytosis (HLH) in
infancy.5 HLH is a hyperinflammatory disorder characterized
by unremitting fever, hepatosplenomegaly, hyperferritinemia,
cytopenia, and sometimes hemophagocytosis and is diagnosed
on the basis of fulfillment of at least five of eight clinical and
laboratory criteria.6,7 Besides PRF1, mutations in genes required
for exocytosis of perforin-containing vesicles may also present
with HLH in infancy. For example, in addition to mutations in
PRF1, familial HLH (FHL) has been associated with mutations
in UNC13D, STX11, and STXBP2.8 Moreover, HLH is also
associated with Griscelli syndrome type 2 and Chediak-
Higashi syndrome caused by mutations in RAB27A and LYST,
respectively, which impair vesicle biogenesis and exocytosis.
So far, there are few data linking defects in cytotoxic lym-
phocyte exocytosis to development of hematologic malig-
nancies. Here, we report the development of an Epstein Barr
virus (EBV)-positive classical Hodgkin’s lymphoma (cHL) in a
patient in remission for HLH caused by biallelic mutations in
STXBP2.
Design and Methods
Patients and controls
The studies were approved by the ethics committee at the
Karolinska Institutet. Written consent was obtained from the patient.   
Western blot analysis of Munc18-2 expression
Peripheral blood mononuclear cells (PBMC) from patients and
healthy controls were lysed in lysis buffer (20 mM Tris, pH 7.4, 1
mM EDTA, 1% Triton X-100, 150 mM NaCl) with protease
inhibitors (Roche). Cells were disrupted and centrifuged for 15 min
at 14,000 g. Protein content was determined by the Bradford assay
(Bio-Rad), and 50 μg protein was loaded per lane and analyzed using
SDS-PAGE separation and Western blotting (NuPAGE, Invitrogen).
The rabbit polyclonal antibodies to Munc18-2 (raised against amino
acids 1-236) or Rab27a were used for Western blotting (both from
Protein Technologies Group).
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Experimental model systems have delineated an important role for cytotoxic lymphocytes in the immunosurveil-
lance of cancer. In humans, perforin-deficiency has been associated with occurrence of hematologic malignancies.
Here, we describe an Epstein-Barr virus-positive classical Hodgkin’s lymphoma in a patient harboring biallelic
mutations in STXBP2, a gene required for exocytosis of perforin-containing lytic granules and associated with
familial hemophagocytic lymphohistocytosis. Cytotoxic T lymphocytes were found infiltrating the tumor, and a
high frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes were detected in peripheral blood.
However, lytic granule exocytosis and cytotoxicity by cytotoxic T lymphocytes, as well as natural killer cells, were
severely impaired in the patient. Thus, the data suggest a link between defective lymphocyte exocytosis and
development of lymphoma in STXBP2-deficient patients. Therefore, with regards to treatment of familial hemo-
phagocytic lymphohistocytosis patients with mutations in genes required for lymphocyte exocytosis, it is impor-
tant to consider both the risks of hemophagocytic lymphohistocytosis and malignancy.
ABSTRACT
Immunohistochemistry
Immunohistochemical stains were performed on deparaffinized
tissue sections in a semi-automated manner with Bond Polymer
Refine and Bond DAB Enhance on a Bond-Max stainer, as recom-
mended by the manufacturer (Vision Biosystems, Leica
Microsystems). Anti-CD3 (LN10, Novocastra), anti-CD8 (4B11,
Novocastra), anti-CD15 (Carb-3, Dako), anti-CD20 (L26, Dako),
anti-CD30 (1G12, Novocastra), anti-CD68 (PG-M1, Dako), anti-
Bcl2 (3.1, Novocastra), anti-Ki67 (MIB-1, Dako), anti-PAX5 (1EW,
Novocastra), anti-perforin (5B10, Novocastra), and anti-granzyme
B (11F1, Novocastra) antibodies were used. Fluorescence in situ
hybridization for EBV-encoded RNA (EBER) was also performed
on a Bond-Max stainer, using fluorescein-conjugated oligonu-
cleotide probes (EBER Probe, Leica Biosystems).
Functional assays
For assessment of NK cell-mediated cytotoxicity, a standard 4-h
51Cr assay was used.9 A value below 10 LU was considered patho-
logical.6 Cytotoxic lymphocyte exocytosis was assessed by flow
cytometric quantification of CD107a surface expression on gated
CD3–CD56+ natural killer (NK) and CD3+CD8+CD57+ effector T
cells in response to incubation with different target cells, as previ-
ously described.10 To quantify responses to EBV, PBMC were
mixed with synthetic peptides pools of LMP-1, BZLF-1, or EBNA-
3A (all JPT Technologies), incubated for 6 h with GolgiPlug (BD
Bioscience) added after 1 h, followed by extracellular staining of
lineage markers and CD107a and intracellular staining of TNF-α.
All samples were acquired on a LSR Fortessa cell analyzer (BD
Biosciences) and analyzed using Flowjo 9.4 (Tree Star).
Results and Discussion
We have already detailed the clinical presentation of a
17-year old previously healthy girl carrying biallelic
STXBP2 mutations c.1294C>A (p.Gln432X) and
c.1634C>T (p.Ser545Leu).11 The combination of the muta-
tions causes a loss of Munc18-2 expression, the protein
encoded by STXBP2 (Figure 1). Briefly, the patient devel-
oped a life-threatening HLH triggered by a primary EBV
infection and was successfully treated with
immunochemotherapy according to a modification of the
HLH-94 protocol.12 Following treatment, the patient was
administered intravenous immunoglobulin once a month
due to hypogammaglobulinemia. Since completion of
treatment, the patient remained in remission of HLH and
did well.
At the age of 20 years, 45 months after the clinical pres-
entation of HLH, the patient developed a rapidly progres-
sive unilateral swelling of the neck (Figure 2A). The
patient complained of malaise and drowsiness, but denied
fever, sweating or weight loss. Computed 18F-labeled fluo-
rodeoxyglucose-positron emission tomography (18F-FDG-
PET) disclosed a localized lymphadenopathy (10×2×2 cm;
Figure 2B). The patient underwent a partial surgical
removal of affected cervical lymph nodes. Light micro-
scopic examination of the tissue revealed morphological
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Figure 1. Munc18-2 expression in a patient with biallelic nonsense
and missense STXBP2 mutations. PBMC from the patient or 2
healthy controls, unstimulated or treated with 500 IU/mL IL-2
overnight, were lysed and protein content was analyzed by SDS-
PAGE and Western blotting. Rabbit polyclonal antibodies for detec-
tion of Munc18-2 and Rab27a were used.
Figure 2. Hodgkin’s lymphoma in a
Munc18-2-deficient patient in remission
for HLH. (A) Unilateral swelling of the left
side of the neck. (B) Increase in FDG-
uptake by pathological mass of the
enlarged left cervical lymph nodes as
revealed by a 18F-FDG-PET/CT scan. (C)
Diagnosis of classical Hodgkin’s lym-
phoma of mixed cellularity by histologi-
cal examination of left cervical lymph
nodes. Panels show sections stained
with hematoxylin and eosin (H&E), anti-
PAX5 (brown) and anti-CD30 (red) anti-
bodies, anti-CD15 antibody, in situ
hybridization for EBV-encoded RNA
(EBER), as well as anti-CD3 or anti-CD68
antibodies, as indicated. The arrowheads
indicate malignant cells with HRS mor-
phology.
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structure effaced by lymphohistiocytic proliferation
(Figure 2C). A population of dispersed, large atypical cells
with Hodgkin-Reed-Sternberg (HRS) morphology could
be identified (Figure 2C). These cells expressed PAX5,
CD15, CD30, and Ki67, transcribed EBER, but were nega-
tive for CD3, CD20, and ALK1 (Figure 2C and data not
shown). Based on these findings, the patient was diagnosed
with EBV+ cHL stage IA of mixed cellularity type. The
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Figure 3. Characterization of tumor infiltrating cytotoxic T lymphocytes and evaluation of peripheral blood cytotoxic lymphocyte function in
a Munc18-2-deficient patient. (A) Characterization of infiltrating lymphocytes by immunohistiochemical examination of left cervical lymph
nodes. Panels show sections stained with anti-CD8, anti-granzyme B, and anti-perforin antibodies, as indicated. (B-E) The arrowheads indicate
malignant cells. (B) Defective exocytosis and cytotoxicity by CTL and NK cells. Freshly isolated or (D) IL-2-stimulated PBMC were mixed with
51Cr-labeled target cells as indicated. Specific lysis was calculated after 4 h of stimulation. Values represent the mean of 10 healthy, age-
matched controls as well as the patient. Bars indicate the SD. One representative experiment of 3 is shown. (C) Freshly isolated or (E) IL-2-
stimulated PBMC were mixed with target cells as indicated. Surface expression of CD107a was quantified after 3 h of stimulation on CTL
or NK cells. Values represent the mean of 30 healthy controls and 4 repeat samples of the patient. Bars indicate the SD. (F) PBMC from a
healthy donor or the patient were mixed with synthetic peptides to the EBV protein BZLF-1 and stimulated for 6 h. Plots display CD107a
and TNF-α expression on CD8+ T cells. (G) Expression of the tumor oncogene Bcl-2 in HRS cells. Panels show sections stained with an anti-
Bcl-2 antibody. The arrowheads indicate malignant cells.
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accompanying population of small lymphocytes was
dominated by CD8+ T cells (Figures 2C and 3A).
Remarkably, spleen size was within normal limits and the
patient did not fulfill clinical HLH criteria at the time of the
cHL diagnosis (hemoglobin 139 g/L; platelets 202×109/L;
neutrophils 1.6×109/L; ferritin 23 μg/L; fasting triglycerides
0.79 mmol/L; fibrinogen 1.8 g/L; sCD25 631 U/mL).
Quantification of EBV in serum revealed only 50-500
copies/mL. One course of standard adriamycin,
bleomycin, vinblastine, and dacarbazine (ABVD)
chemotherapy resulted in complete remission, as docu-
mented clinically and by 18F-FDG-PET. The patient com-
pleted four courses of ABVD and local radiotherapy, fol-
lowed by allogeneic hematopoietic stem cell transplanta-
tion (HSCT).
Experimental models have indicated important roles for
NK and γδ T cells in perforin-mediated control of B-cell
lymphomas.13 Moreover, human tonsilar NK cells can
restrict EBV-mediated transformation though IFN-γ pro-
duction.14 However, in our patient, among tumor infiltrat-
ing lymphocytes, very few CD56+ cells were observed,
whereas CD3+ and CD8+ cells were abundant, with many
expressing granzyme B and/or perforin (Figure 2C,3A, and
data not shown). Thus, the immunological response to the
lymphoma cells appeared to be dominated by cytotoxic T
cells (CTLs). Experimental models have shown a central
role for CD8+ T cells in protective immunity to EBV.15,16
Longitudinal analyses of lymphocyte cytotoxicity in the
patient demonstrated an absence of exocytosis and cyto-
toxicity by both CTL and NK cells (Figure 3B,C), which
was partially restored by IL-2 stimulation (Figure 3D,E).
Relative to a healthy control, EBV-specific T cells in the
patient produced TNF-α, but displayed impaired degranu-
lation in response to BZLF-1 peptides (Figure 3F).
Compared to healthy controls, in whom 78% of the TNF-
α+ CD8+ T cells also were CD107a+, only 14% of the TNF-
α+ CD8+ T cells were CD107a+ in our patient. By compar-
ison, peptide pools to EBNA-3A or LMP-1 did not elicit
significant T-cell responses in the patient (data not shown).
Of note, mouse models indicate tumor immunogenicity is
dictated by oncogene expression.17,18 Whereas overexpres-
sion of Myc or loss of p53 does not confer immunogenic-
ity, overexpression of Bcl-2 does. cHL cells in our patient
expressed Bcl-2 (Figure 3G), possibly reflecting impaired
immunological sculpting.17-19
In summary, the present patient suggests the possibility
of an association of hypomorphic STXBP2mutations with
lymphoma. The cumulative dose of etoposide received
during HLH-therapy was low (0.2 g/m2). Furthermore,
etoposide-induced malignancies are typically myeloid-
derived.20 Thus, impaired immunosurveillance of EBV-
infected and transformed cells is a plausible cause of cHL
in our patient.21 Notably, we have previously reported
development of acute myeloid leukemia and myelodys-
plastic syndrome in 2 STX11-deficient patients who
received 3.1 and 23.9 g/m2 of etoposide/teniposide,
respectively, so these malignancies could also be second-
ary to chemotherapy.22 Strengthening the notion of a
causal link between defective exocytosis and lymphoma,
Pagel and colleagues recently reported a patient homozy-
gous for a c.1247-1G>C splice error mutation in STXBP2
who initially presented with cHL stage IIIB and HLH fea-
tures at the age of nine years.23 The patient was successful-
ly treated for lymphoma, but an HLH relapse occurred at
the age of ten years. Thus, similar to what has been
reported in patients with biallelic mutations in PRF1 or
LYST, which both impair lymphocyte cytotoxicity,3,4,24
patients with severe biallelic mutations in STXBP2 that
abrogate exocytosis most likely present with HLH in
infancy, whereas patients with hypomorphic mutations
may present with hematologic malignancies later in life.
Notably, the present patient did not manifest HLH at the
time of lymphoma development. Therefore, studies of the
frequencies of mutations in FHL-associated genes are war-
ranted in lymphoma patients. An interesting question is
whether mutations in certain FHL-associated genes more
strongly predispose to development of lymphoma than
others. Although the genes are all required for lymphocyte
cytotoxic function, PRF1mutations do not prevent release
of granzymes and other granule constituents, whereas
mutations in UNC13D, STXBP2, and STX11 do. Whereas
perforin-deficiency specifically impairs lymphocyte cyto-
toxicity, the latter genes also affect other exocytic, but
non-cytotoxic, functions of diverse immune cells, as well
as platelets. This may have consequences for susceptibility
to lymphoma development. 
These findings have important clinical implications.
Allogeneic hematopoietic stem cell transplantation
(HSCT) represents the only cure for FHL. The cumulative
risk of HLH and malignancies should be taken into consid-
eration when determining whether to perform HSCT. We,
therefore, currently favor HSCT in patients with defined
disease-causing mutations in FHL genes. A molecular diag-
nosis may be difficult to obtain in some patients, e.g. due
to non-coding aberrations.25 In this setting, reproducible
defects in cytotoxic lymphocyte function also may war-
rant HSCT.
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